- Home
- CRGX vs DENN Comparison
CRGX vs DENN Comparison
Compare CRGX & DENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- DENN
- Stock Information
- Founded
- CRGX 2021
- DENN 1953
- Country
- CRGX United States
- DENN United States
- Employees
- CRGX N/A
- DENN N/A
- Industry
- CRGX
- DENN Restaurants
- Sector
- CRGX
- DENN Consumer Discretionary
- Exchange
- CRGX Nasdaq
- DENN Nasdaq
- Market Cap
- CRGX 190.0M
- DENN 203.4M
- IPO Year
- CRGX 2023
- DENN 1989
- Fundamental
- Price
- CRGX $4.25
- DENN $3.82
- Analyst Decision
- CRGX Hold
- DENN Strong Buy
- Analyst Count
- CRGX 7
- DENN 6
- Target Price
- CRGX $4.67
- DENN $7.46
- AVG Volume (30 Days)
- CRGX 569.8K
- DENN 850.5K
- Earning Date
- CRGX 05-08-2025
- DENN 05-05-2025
- Dividend Yield
- CRGX N/A
- DENN N/A
- EPS Growth
- CRGX N/A
- DENN N/A
- EPS
- CRGX N/A
- DENN 0.33
- Revenue
- CRGX N/A
- DENN $453,997,000.00
- Revenue This Year
- CRGX $58.18
- DENN $7.51
- Revenue Next Year
- CRGX N/A
- DENN $1.98
- P/E Ratio
- CRGX N/A
- DENN $11.61
- Revenue Growth
- CRGX N/A
- DENN N/A
- 52 Week Low
- CRGX $3.00
- DENN $2.85
- 52 Week High
- CRGX $25.45
- DENN $7.73
- Technical
- Relative Strength Index (RSI)
- CRGX 53.57
- DENN 46.49
- Support Level
- CRGX $3.78
- DENN $3.63
- Resistance Level
- CRGX $4.27
- DENN $4.13
- Average True Range (ATR)
- CRGX 0.18
- DENN 0.19
- MACD
- CRGX 0.03
- DENN -0.05
- Stochastic Oscillator
- CRGX 88.79
- DENN 16.96
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About DENN Denny's Corporation
Denny's Corp is one of America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees.